$1.24
-0.01 (-0.80%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PMVP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 6 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +1 more) · FINRA short interest 10.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.NCT07372625Metformin Cmax geometric mean ratioOpen-label · Treatment | Phase 1 | Recruiting | Drug: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt | TP53 Y220C Mutation, Advanced Solid Tumors | 14 | Mar 2027 | ≤ 224 d | 2026-08-12 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapoptNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2026-08-15 | — | 2026-08-10 |
| A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy ParticipantsNCT06362642Characterize the Maximum Plasma Concentration (Cmax) of PC14586 when co-administered with itraconazole in healthy participants.Open-label · Other | Phase 1 | Completed | Drug: PC14586, Itraconazole | Healthy Volunteers | 12 | 2024-10-22actual | — | 2024-11-13 |
| A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy ParticipantsNCT06054464Part 1: Characterize the Maximum Plasma Concentration (Cmax) of PC14586 when co-administered with rabeprazole.Non-randomized · Open-label · Other | Phase 1 | Completed | Drug: PC14586, Rabeprazole, Famotidine | Healthy Volunteers | 28 | 2023-11-03actual | — | 2024-11-13 |
| AME Study of [14C]-PC14586 in Healthy Male ParticipantsNCT05523687Characterize Maximum Plasma Concentration (Cmax) of PC14586 and PC14586 metabolite M1 (PC16163).Open-label · Other | Phase 1 | Completed | Drug: [14C]-PC14586 | Healthy Male Volunteers | 8 | 2022-11-30actual | — | 2022-12-20 |
| Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese VolunteersNCT05249348Part 1: Effect of a high-fat meal on AUClastRandomized · Open-label · Other | Phase 1 | Completed | Drug: PC14586 | Healthy Volunteers | 34 | 2022-06-09actual | — | 2024-11-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19